Technical

Claude View

The Price Picture

Biocon's tape is telling a subtler story than the Numbers tab. Revenue tripled and FCF flipped from −₹748 cr to +₹1,718 cr — yet the stock sits 16 percent below its November 2025 high of ₹424.95, printed a fresh death cross one week ago (April 10), and trades ₹16 under both its 50-day and 200-day moving averages. Below that, momentum has just turned: the MACD histogram flipped positive on April 17 and RSI lifted off an oversold 31 on April 7. The chart is not confirming the FCF inflection yet — it is digesting the June-2025 QIP dilution and waiting for the next leverage print.

1. Snapshot

2. The critical chart — 3-year price with 50/200 SMA

Price is below the 200-day (₹358.10 vs ₹374.49, a 4.4 percent discount). The three-year regime is sideways-with-higher-lows — a rolling range between roughly ₹300 and ₹425, not a trend.

3. Relative strength vs INDA

Biocon has outperformed the broad Indian market by roughly 23 points over three years (146 vs 123). The gap peaked at 41 points in November 2025 — the QIP placement window — and has narrowed by 18 points since. No sector ETF for Indian healthcare is included, and the peer basket is empty (0 members) per manifest — relative strength here is measured only against the broad Indian market.

4. Momentum — RSI and MACD

RSI bounced from an oversold 31 on April 7 to 48 today — a six-session recovery. The MACD histogram just flipped positive on April 17 (+0.77) after eight sessions negative. Both fast gauges argue the sellers are exhausted for now; neither is strong enough yet to call a trend change on its own.

5. Volume and conviction

Recent selling has been on thin volume — the last five sessions averaged 2.5 M shares against a 50-day average of 3.4 M, and the April 10 death-cross session itself printed under average. The two largest recent spikes (September 19, 2025 at 14.2 M shares; February 12, 2026 at 8.3 M) were both near upside resolution days, not breakdowns. The tape is not confirming distribution.

6. Volatility regime

Current 30-day realized vol is 31.8 percent — solidly in the normal band (p20 = 23.4, p80 = 38.1). February-March 2026 saw vol compress to multi-year lows near 16 percent; the April reopening into mid-30s reflects the April 7 sell-off and April 10 cross, not a structural stress event. No panic is priced in.

7. Scorecard and stance

Stance: Neutral on a 3-to-6 month horizon. Net score 0/6. The long-term uptrend is intact but paused; the near-term tape flipped from sellers to buyers this week. Biocon needs to reclaim ₹378 (the 100-day and the rolling December 2025 base) to invalidate the death cross and re-engage the FCF-inflection narrative Numbers laid out. A daily close below ₹343 — the March-April 2025 swing low and 10 percent under spot — would confirm a test of the ₹318 52-week low and put the QIP overhang back at the centre of the story.

Cross-ref with Numbers: Quant argued the rerate unlocks when net debt / EBITDA compresses below 2.0x (from 2.88x). The tape is consistent with that thesis being in front of the reader, not behind it — the November 2025 QIP-driven surge to ₹425 ran ahead of the numbers and has since been given back. The chart is waiting for the next balance-sheet print, not denying the thesis.